| |
HEP-DART presentations 3 Dec - 7, 2017
|
| |
| |
NASH, HBV, HCV
http://www.infectiousdiseasesonline.com/hepdart_presentations_3dec/
a few selected.....
Clinical Challenges in HCV infection
Dr. M. Sulkowski, Johns Hopkins University, USA
Elimination of HCV: The DC Story
Dr. H. Masur, NIH, USA
The French and European Approach Towards Hepatitis Elimination
Dr. T. Asselah, Hôpital Beaujon, France
Global Strategies to Eliminate Hepatitis B (ICE-HBV)
Dr. P. Revill, Victorian Infectious Diseases Reference Laboratory, Australia
Epidemiologic impact of expanding chronic hepatitis C (CHC) treatment in people who inject drugs (PWID) in the United States (US): a mathematical model using data from the C-EDGE CO-STAR Study
Dr. M. Robertson, Merck, USA
Access to HIV, HBV, and HCV Antiviral Agents Globally
Dr. J. Martin, Gilead Sciences, USA
New directions towards functional cure of Chronic Hepatitis B
Dr. L. Blatt, Johnson & Johnson, USA
Controlling HBsAg as a Key Component of a Combination Strategy to Affect an HBV Cure
Dr. M. Sofia, Arbutus Biopharma, USA
Endpoints and New Targets for Curing Hepatitis B
Dr. S. Locarnini, Victorian Infectious Diseases Reference Laboratory, Australia
Core Antibody: anti-HBc What is the Core of the Story?
Dr. R. Gish, Hepatitis B Foundation, USA
Regulatory landscape for NASH
Dr. V. Miller, Forum for Collaborative Research, USA
Validation of a novel Transient Elastography for the measurement of liver fibrosis
Dr. J. Dong, Humanity and Health Liver Clinic, Hong Kong
| |
| |
| |
|
|
|
